20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

Directions Website

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

10/30/2026

We’re heading to CNS Summit 2026 in Boston in a few days.

Our team is especially looking forward to connecting with industry leaders to discuss the challenges facing research today and explore novel, practical solutions to overcome them, improve trial ex*****on, and ultimately create better experiences for patients.

One area where we're helping address these challenges is ophthalmic assessments. Whether they are a core endpoint or required for safety monitoring, the right approach can help reduce site burden, improve patient access, maintain data quality, and keep study timelines moving.

At 20/20 Onsite, we're helping make that possible by bringing ophthalmic expertise, specialized equipment, and certified staff directly to the point of need.

If you’re attending CNS Summit and your current or upcoming trials include ophthalmic assessments, let’s connect.

📍 CNS Summit 2026
📅 November 1–4

DM us to t

10/28/2026

Mobile Vision Clinics vs. In-Clinic Assessments: Which is better for ocular endpoints?

The answer depends on your trial, your sites, and your participants.

When it comes to collecting reliable ocular endpoint data, the priority isn't necessarily where assessments take place. It's ensuring consistent testing conditions, qualified staff, and high-quality data across every visit.

For sponsors and CROs, that means choosing an assessment model that fits the needs of the study:
• In-clinic assessments: Ideal when sites already have the necessary ophthalmic equipment and certified staff.
• Mobile Vision Clinics: Bring ophthalmic assessments closer to participants, reducing travel burden and improving accessibility.
• Mobile Vision Pods: Provide dedicated, semi-permanent assessment spaces for longer-term studies.
• Mobile Clinic Suites: Bring specialized equipment and certified staff into existing clinical spaces.

At 20/20 Onsite, we believe the right approach is to protect endpoint quality while making participation easier for patients.

Our latest article explores the advantages of each model and how sponsors can determine the best fit for their clinical trials.

Read the full article: https://hubs.ly/Q04CzYQJ0

10/27/2026

Sometimes, the biggest impact we make isn't about the technology or the assessments themselves.

It's about helping a patient feel comfortable enough to receive the care they need.

For children, especially those with sensory sensitivities or unique care needs, even a routine eye exam can be challenging.

Our clinical teams understand that delivering high-quality care also means being patient, compassionate, and adaptable to each individual's needs.

Learn more about our patient-centered approach to ophthalmic assessments:
https://hubs.ly/Q04BDB_X0

10/26/2026

Not every clinical research site has the equipment, staff, or specialized expertise needed to conduct ophthalmic assessments.

And when those assessments are required by a protocol, that can quickly become a challenge for sponsors, CROs, and research teams.

That's where point-of-need ophthalmic assessments can make a real difference.

We're proud to work with organizations like Syneos Health to bring specialized ophthalmic services directly to clinical research settings, helping teams meet protocol requirements without adding unnecessary complexity.

See how we're helping sponsors and CROs overcome ophthalmic assessment challenges in clinical trials: https://hubs.ly/Q04BDBsz0

10/23/2026

We’re heading to CNS Summit 2026, November 1–4!

CNS Summit brings together leaders from across pharma, biotech, clinical research, technology, and the broader life sciences ecosystem to explore what’s next in drug development and clinical trial ex*****on.

At 20/20 Onsite, we help sponsors and CROs make ophthalmic assessments easier to execute through a flexible, point-of-need model designed to reduce patient burden, support retention, maintain high-quality data, and keep studies moving.

If you're there, you might run into the team from 20/20 Onsite:
Sonali Bloom, Chief Executive Officer
Mark Epstein, Vice President, Sales

If you’ll be at CNS Summit and want to connect about a current or upcoming study, send us a DM to schedule a meeting with Sonali or Mark.

See you in Boston.

10/22/2026

Many ocular endpoint problems don’t start at the site. They start much earlier, in the protocol.

A BCVA procedure that isn’t fully specified. An OCT scan protocol left open to interpretation. A visit schedule that doesn’t account for dilation or testing sequence.

Those details can lead to deviations, rescans, inconsistent data, and, eventually, protocol amendments once a trial is underway.

And amendments are not a small issue. 76% of Phase 1–4 protocols now have at least one amendment, and the process, from identifying the need for an amendment to final approval, takes an average of 260 days.

Our latest Eyes on Research article looks at how sponsors can bring ophthalmic expertise into protocol development earlier, including:
• How to align assessments with the actual endpoint
• What should be specified for BCVA, OCT, IOP, and other assessments
• How to evaluate site feasibility before activation
• How better protocol planning can reduce the risk of amendments later
The goal is simple: protect the ocular endpoint before the first participant is ever assessed.

Read the full article: https://hubs.ly/Q04BB-Mb0

10/21/2026

We’re back from the SCRS Global Site Solutions Summit, and a few themes stood out:

- Community engagement is not the same as outreach. Trust takes time. Clinical research should aim to be a resource for communities, not simply show up when participants are needed.
- Recruitment challenges are pushing teams to get more creative. Finding the right patients means rethinking where they are reached and how to reduce barriers to participation.
- Open Label Extension studies can also play an important role in attracting patients by offering continued access to treatment.

For us, it reinforced something we think about often at 20/20 Onsite: better trial ex*****on starts with making participation easier for patients and sites.

If your team is working through challenges related to recruitment, access, site capacity, or ophthalmic assessment, reach out. We’d be happy to talk through where we may be able to help.

And for those we connected with at SCRS, we’d love to keep the conversation going.

10/16/2026

What if patients could be pre-screened and qualified before clinical sites were fully activated?

That's exactly what we help sponsors accomplish.

Here's a case study from one sponsor. 82% of the first 34 participants enrolled had already been pre-screened and qualified through 20/20 Onsite's mobile ophthalmic assessments.

By bringing protocol-specific assessments directly to patients, we helped the sponsor:
✅ Accelerate enrollment and data collection
✅ Identify qualified participants earlier
✅ Reduce patient travel and screening burden
✅ Improve the overall patient experience

The accelerated enrollment and resulting data collection also contributed to the trial earning FDA Fast Track designation.

For sponsors and CROs, this represents a significant opportunity to rethink when enrollment efforts can begin.

The takeaway? You don't have to wait for your sites to activate to start making progress toward enrollment goals.

Read the full case study:
https://hubs.ly/Q04BcgTr0

10/15/2026

We’re at the SCRS Global Site Solutions Summit in Orlando.

If you’re here, come find the 20/20 Onsite team.

We’re always up for a conversation about the operational side of ophthalmic assessments in clinical trials, especially when sites are dealing with patient travel, staffing, equipment, timelines, or assessments that are difficult to execute locally.

Our goal is simple: bring the right ophthalmic expertise, equipment, and staff to the point of need, so sites and sponsors have one less thing to solve.

Adam, Sam, Chloe, and Mark are onsite throughout the summit.

Want to connect while you’re here? Grab some time with the team:
https://hubs.ly/Q04z86tX0

See you at SCRS.

10/13/2026

We’re headed to Orlando this week for the SCRS Global Site Solutions Summit!

SCRS is always a valuable opportunity to hear directly from clinical research sites about what is working, where trials are getting stuck, and how sponsors, CROs, sites, and partners can work together to make study ex*****on easier for everyone involved.

If your protocol includes ophthalmic assessments and you are dealing with site capacity, patient travel, staffing, equipment, or an unexpected protocol change, we’d love to connect.

Our team attending:
Adam Merola, Sr. Director, Trial Delivery
Sam Larberg, Account Executive
Chloe Armstrong, Project Manager
Mark Epstein, Vice President, Sales

At 20/20 Onsite, we bring ophthalmic assessments to the point of need, helping reduce patient burden, support sites, protect data quality, and keep clinical trials moving.

If you’ll be at SCRS, come find us or book time with our team in advance:
https://hubs.ly/Q04zTSx70

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.